The interface of multiple sclerosis and antiphospholipid antibodies

Thrombosis Research

Volumn 114, Issue 5-6 SPEC. ISS., 2004, Pages 477-481

  Chapman, Joab ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

2 glycoprotein I; 2 GPI; Antiphospholipid antibodies; antiphospholipid antibodies; antiphospholipid syndrome; Antiphospholipid syndrome; aPLAb; APS; Brain imaging; magnetic resonance imaging; MRI; MS; Multiple sclerosis; multiple sclerosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIMALARIAL AGENT; AUTOANTIGEN; AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; BETA2 GLYCOPROTEIN 1; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; GLATIRAMER; HEPARIN DERIVATIVE; IMMUNOGLOBULIN; MITOXANTRONE; PHOSPHOLIPID ANTIBODY; STEROID;

ANTIPHOSPHOLIPID SYNDROME; BRAIN INJURY; CONFERENCE PAPER; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISEASE EXACERBATION; ELECTROPHYSIOLOGY; FIBRIN DEPOSITION; HUMAN; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; SERUM FACTOR; WHITE MATTER;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BRAIN; CLINICAL TRIALS; DIAGNOSIS, DIFFERENTIAL; HUMANS; MULTIPLE SCLEROSIS; PHOSPHOLIPIDS;

EID: 7044245634     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2004.06.016     Document Type: Conference Paper

References (22)

1. Karussis D., Leker R.R., Ashkenazi A., Abramsky O. A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: Do they represent a new nosological entity? Ann. Neurol. 44:1998;629-634
2. Roussel V., Yi F., Jauberteau M.O., Couderq C., Lacombe C., Michelet V., et al. Prevalence and clinical significance of anti-phospholipid antibodies in multiple sclerosis: A study of 89 patients. J. Autoimmun. 14:2000;259-265
3. Sugiyama Y., Yamamoto T. Characterization of serum anti-phospholipid antibodies in patients with multiple sclerosis. Tohoku J. Exp. Med. 178:1996;203-215
4. Cordoliani M.A., Michon_Pasturel U., Rerat K., Arvieux J., Masy E., Hachulla E., et al. Multiple sclerosis and antiphospholipid antibodies: Study of 62 consecutive patients. Rev. Med. Intern./Fond. Soc. Natl. Fr. Med. Int. 19:1998;635-639
5. Tourbah A., Clapin A., Gout O., Fontaine B., Liblau R., Batteux F., et al. Systemic autoimmune features and multiple sclerosis: A 5-year follow-up study. Arch. Neurol. 55:1998;517-521
6. D'Olhaberriague L., Levine S.R., Salowich-Palm L., Tanne D., Sawaya K.L., Aurora T.K., et al. Specificity, isotype, and titer distribution of anticardiolipin antibodies in CNS diseases. Neurology. 51:1998;1376-1380
7. Molad Y., Sidi Y., Gornish M., Lerner M., Pinkhas J., Weinberger A. Lupus anticoagulant: correlation with magnetic resonance imaging of brain lesions. J. Rheumatol. 19:1992;556-561
8. Chapman J., Abu-Katash M., Inzelberg R., Yust I., Neufeld M.Y., Vardinon N., et al. Prevalence and clinical features of dementia associated with the antiphospholipid syndrome and circulating anticoagulants. J. Neurol. Sci. 203-204:2002;81-84
9. Inaba Y., Ichikawa M., Inoue A., Itoh M., Kyogashima M., Sekiguchi Y., et al. Plasma thrombin-antithrombin III complex is associated with the severity of experimental autoimmune encephalomyelitis. J. Neurol. Sci. 185:2001;89-93
10. Garcia C.O., Kanbour-Shakir A., Tang H., Molina J.F., Espinoza L.R., Gharavi A.E. Induction of experimental antiphospholipid antibody syndrome in PL/J mice following immunization with beta 2 GPI. Am. J. Reprod. Immunol. 37:1997;118-124
11. Shrot S., Katzav A., Korczyn A.D., Litvinju Y., Hershenson R., Pick C.G., et al. Behavioral and cognitive deficits occur only after prolonged exposure of mice to antiphospholipid antibodies. Lupus. 11:2002;736-743
12. Rovaris M., Viti B., Ciboddo G., Capra R., Filippi M. Cervical cord magnetic resonance imaging findings in systemic immune-mediated diseases. J. Neurol. Sci. 176:2000;128-130
13. Rovaris M., Viti B., Ciboddo G., Gerevini S., Capra R., Iannucci G., et al. Brain involvement in systemic immune mediated diseases: Magnetic resonance and magnetisation transfer imaging study. J. Neurol., Neurosurg., Psychiatry. 68:2000;170-177
14. Assaf Y., Ben-Bashat D., Chapman J., Peled S., Biton I.E., Kafri M., et al. High b-value q-space analyzed diffusion-weighted MRI: Application to multiple sclerosis. Magn. Reson. Med. 47:2002;115-126
15. Paran D., Drory V., Elkayam O., Hilkevich O., Levartovsky D., Litinsky I., et al. An electrophysiological study and brain MRI evaluation of patients with CNS manifestations of the antiphospholipid syndrome as compared to patients with multiple sclerosis. Arthritis Rheum. 48:2003;1113
16. Cuadrado M.J., Khamashta M.A., Ballesteros A., Godfrey T., Simon M.J., Hughes G.R. Can neurological manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature. Medicine. 79(1):2000;57-68
17. IJdo J.W., Conti_Kelly A.M., Greco P., Abedi M., Amos M., Provenzale J.M., et al. Anti-phospholipid antibodies in patients with multiple sclerosis and MS-like illnesses: MS or APS? Lupus. 8:1999;109-115
18. Lider O., Baharav E., Mekori Y.A., Miller T., Naparstek Y., Vlodavsky I., et al. Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with low doses of heparins. J. Clin. Invest. 83:1989;752-756
19. Ruiz_Irastorza G., Khamashta M.A. Warfarin for multiple sclerosis? QJM: Mon. J. Assoc. Phys. 93:2000;497-499
20. Santiago-Raber M.L., Baccala R., Haraldsson K.M., Choubey D., Stewart T.A., Kono D.H. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J. Exp. Med. 197:2003;777-788
21. Speciale L., Saresella M., Caputo D., Ruzzante S., Mancuso R., Calvo M.G., et al. Serum auto antibodies presence in multiple sclerosis patients treated with beta-interferon 1a and 1b. J. Neurovirol. 6:2000;S57-S61
22. Colosimo C., Pozzilli C., Frontoni M., Farina D., Koudriavtseva T., Gasperini C., et al. No increase of serum autoantibodies during therapy with recombinant human interferon-beta1a in relapsing-remitting multiple sclerosis. Acta Neurol. Scand. 96:1997;372-374